- | 9 Meters
John Temperato: CEO of 9 Meters Biopharma
John Temperato, President and Chief Executive Officer of 9 Meters Biopharma, speaks with BioBoss host John Simboli about leadership in biopharma and how 9 Meters is advancing drug candidates for patients with rare and unmet gastrointestinal disorders including short bowel syndrome and celiac disease.
- | Heat Biologics
Heat Biologics shares sizzle as new phase II NSCLC data put it on path to possible pivotal trial
- | Valneva
Valneva Eyes Head-to-Head Vaccine Trial
Thomas Lingelbach, chief executive officer at Valneva SE, discusses the company’s vaccine trials, the difference in processes in working with the U.K. versus the EU and production of the vaccine. He speaks on “Bloomberg Markets: European Open.” (Source: Bloomberg)
- | 9 Meters
Raleigh company working to develop a cure for celiac disease
“One of the beauties of being in biotech is that at the end of what you do you improve the lives of debilitating diseases,” said John Temperato, CEO of 9 Meter BioPharma. Temperato and his team of researchers have spent years working on a cure for celiac disease, which impacts 3.5 million people in the United States alone.
- | Immuneering
Disease Cancelling Technology Emulates Sound Cancelling Technology to Mute Cancer
Immuneering prefers the hum of purposeful activity to mere noise. That helps explain why the company develops drugs to dampen the cacophony of cell signalling known as cancer. To identify drug candidates, Immuneering uses its own Disease Cancelling Technology. Characteristically, the company has been quiet about the technology, which represents more than a decade’s worth of diligent effort. But now that the technology is ready, Immuneering is ready to talk about it in calm, assured tones.
- | CalciMedica
CalciMedica’s Auxora reduces D-Dimer levels in Covid-19 trial
CalciMedica has reported positive clinical data from the trial of its lead clinical compound, Auxora, in patients with severe Covid-19 pneumonia.
- | INmune Bio
Quellor clinical study underway to lessen COVID-19 symptoms
That drug is called Quellor. INmune BIO said if its drug is approved by the FDA, the hope is it could reduce symptoms of COVID-19 down to symptoms similar to a common cold. Doctors at the University of Louisville Jewish Hospital are currently accepting patients 65 and up to be a part of the clinical study.
- | Scynexis
Ibrexafungerp advances the fight against fungus
In December, SCYNEXIS Inc. reported progress on ibrexafungerp’s intravenous (IV) formulation and provided an update on the therapy’s ongoing Phase 3 studies in the hospital setting. SCYNEXIS has completed preclinical testing of its liposomal IV formulation of ibrexafungerp, and is moving the program into human trials in South Africa.
